INNOVATE Corp. Portfolio Company R2 Technologies Announces First Year Commercial Milestone and Clinical Data Presentation at Recent ASLMS Annual Meeting
100 GLACIAL® Devices for Revolutionary Skin Treatment Shipped
Over 15,000 Patient Treatment Cycles Performed To-Date
Last week, R2 announced that it has shipped 100 GLACIAL® devices to customers globally. R2 customers have performed over 15,000 GLACIAL® treatment cycles, helping patients reach their skin goals by reducing inflammation and revealing younger looking skin. R2 reached this significant achievement within its first year of commercial sales of the GLACIAL® Rx platform.
R2 also recently announced that data related to GLACIAL® Rx was presented during the annual meeting of the
“These important milestones are testaments to the groundbreaking work happening at R2. The team has generated incredibly strong momentum despite the continued impact of the pandemic, delivering 100 devices since GLACIAL® Rx’s commercial launch just one year ago, and we are thrilled with the overwhelmingly positive customer feedback we have received on the GLACIAL® Rx platform. Additionally, having the opportunity to present clinical data at the ASLMS Annual Meeting is an exciting development that underscores the market potential for R2 technologies. We look forward to continuing to support the growth of R2’s innovative product pipeline as we seek to drive meaningful value for our stakeholders,” said
GLACIAL® Rx is the first-to-market controlled cooling treatment of its kind, FDA-cleared to temporarily reduce inflammation, pain, swelling, and to remove benign lesions. GLACIAL® Rx CryoAesthetic™ treatments can be delivered with or without topicals, depending on the goals of the patient. GLACIAL® has high patient satisfaction rates, with 100% of patients surveyed stating they would have the treatment again.
“The data presented at the ASLMS meeting is the first academic data presented that demonstrate the benefits of controlled cooling to both improve the appearance of inflamed, photodamaged skin, and provide some symptomatic relief from painful psoriatic plaques,” added Holt, who has served as R2’s President and CEO since 2019.
R2 will be celebrating with hashtag #Glacial100 in the coming weeks and is actively taking orders from aesthetic providers who want to offer GLACIAL® Rx controlled cooling treatments in their practices. To learn more about
Cautionary Statement Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release contains, and certain oral statements made by our representatives from time to time may contain, forward-looking statements, including those that may be identified by words such as “will,” “intend,” “expect,” “anticipate,” “should,” “could” and similar expressions, all of which involve risks, assumptions and uncertainties, many of which are outside of the Company’s control, and are subject to change. All forward-looking statements speak only as of the date made, and unless legally required, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. The Company’s actual results could differ materially from those expressed or implied in any forward-looking statements due to a variety of important factors, both positive and negative, that may be revised or supplemented in subsequent statements and reports filed with the
Source: INNOVATE Corp.